Medexus Pharmaceuticals Inc.

About Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals, Inc. is a leading innovative specialty pharmaceutical company with a scalable North American business model. It has a fully integrated infrastructure including commercial operations, supply chain, regulatory, medical affairs, and salesforce, and a portfolio of specialty and rare disease products aimed at supporting growth for the next decade.

Products & Services

Product Portfolio:Features leading products addressing various diseases including allergy, dermatology, hematology (rare disease), oncology (rare disease), and rheumatology.

GRAFAPEX (treosulfan) for Injection:A product recently launched in the US, with positive fiscal Q1 2026 results and CMS approval for New Technology Add-On Payment (NTAP) for eligible cases in fiscal year 2026.

Specialties

Specialty Pharmaceuticals Rare Disease Treatments Allergy Dermatology Hematology Oncology Rheumatology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 30000000 MR: - FA: $30,000,000 FAN: 30000000	D: 2025-01-28 FD: 2025-01-28	6 investors
2	RT: Debt T: - FT: Debt	A: 58500000 MR: - FA: US$58.5 million FAN: 58500000	D: 2023-03-08 FD: 2023-03-08	1 investors

Public Offering Latest

2025-01-28

$30.0M

6 investors (Pro only)

Debt 2023-03-08

$58.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael Mueller

Chair of the Board

K

Ken d'Entremont

Chief Executive Officer and Director

H

Harmony P. Garges

Director

B

Benoit Gravel

Director

S

Stephen Nelson

Director

N

Nancy Phelan

Director

View 7 more team members with Pro

Unlock Full Team Directory

Recent News